ticagrelor / Generic mfg. - LARVOL DELTA

Dual Inhibition Strategy in Managing Neuronal Autophagy in PTZ-Induced Kindling in Mice: A Pharmacological Perspective on P2Y12 and SGLT2 Inhibitors. (PubMed, Eur J Pharmacol) - "This study demonstrated neuroprotective potential of dapagliflozin and ticagrelor in PTZ-induced kindling model. The therapy mitigated oxidative stress, restored E/I neurotransmission, promoted GABA receptor trafficking, and maintained neuronal integrity, suggesting its promising role in managing epilepsy."

Journal • Preclinical • CNS Disorders • Epilepsy • AMPK • BECN1 • GABARAP • mTOR • SQSTM1

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis (ASH 2025) - "The study population was divided into two main cohorts: 1) Cohort 1: CLLpatients in remission treated with covalent BTKi (ibrutinib/acalabrutinib/zanubrutinib) concurrentlytreated with AC (rivaroxaban/apixaban/edoxaban/dabigatran) or AP agents (acetylsalicylicacid/clopidogrel/prasugrel/ticagrelor/ticlopidin), and 2) Cohort 2: CLL patients in remission treated withcovalent BTKi (ibrutinib/acalabrutinib/zanubrutinib) not concurrently treated with AC or AP agents.Cohort 1 was further subdivided into two groups: those treated only with AC and those treated only withAP. CLL patients in remission treated with covalent BTKis experience a significant risk ofbleeding events. This risk is substantially elevated when covalent BTKis therapy is combined with eitheranticoagulant or antiplatelet agents. Notably, our findings indicate no discernible difference in bleedingrisk between AC or AP agents when used concurrently with covalent BTKis."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia

Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis. (ASH 2025) - "The CAR-T cohort included patients who received anyFDA-approved CAR-T product (axi-cel, tisa-cel, liso-cel)...Propensity score matching (1:1, nearest neighbor, caliper 0.1) was performed to balance baselinecharacteristics, including age, sex, race, hypertension, diabetes, hyperlipidemia, chronic ischemic heartdisease, chronic kidney disease (all stages), atrial fibrillation, prior ischemic heart disease, priorthromboembolic events, and use of aspirin, warfarin, apixaban, clopidogrel, ticagrelor, or rivaroxabanbefore CAR-T cell therapy... In this large propensity score–matched analysis of patients with relapsed or refractory NHL, CAR-Ttherapy was associated with a substantially higher 90-day risk of venous thromboembolism and acutelimb ischemia in the early post–CAR-T period. These findings highlight the need for close clinicalmonitoring and the potential role of preventive strategies, such as the use of prophylacticanticoagulation in patients with a low risk of bleeding."

Clinical • Atrial Fibrillation • B Cell Lymphoma • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Diffuse Large B Cell Lymphoma • Dyslipidemia • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Ischemic stroke • Lymphoma • Myocardial Infarction • Nephrology • Non-Hodgkin’s Lymphoma • Respiratory Diseases • Venous Thromboembolism

Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. (PubMed, Clin Cardiol) - "The CYP3A5 rs776746 CC genotype is a significant genetic biomarker for ticagrelor-induced dyspnea. Pre-emptive genotyping could enable personalized antiplatelet therapy, such as alternative P2Y₁₂ inhibitors for high-risk CC carriers, to improve patient safety."

Adverse drug reaction • Journal • Acute Coronary Syndrome • Cardiovascular • Pulmonary Disease • CYP3A4 • CYP3A5

Ticagrelor promotes arterial healing and shows superiority to clopidogrel in preventing neoatherosclerosis. (PubMed, Blood Vessel Thromb Hemost) - No abstract available

Head-to-Head • Journal • Cardiovascular

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hematological Disorders • Thrombosis

ACS: Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea (clinicaltrials.gov) - P=N/A | N=110 | Recruiting | Sponsor: Acibadem University

New trial • Acute Coronary Syndrome • Cardiovascular • Pulmonary Disease

PANTHEON: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (clinicaltrials.gov) - P3 | N=2570 | Not yet recruiting | Sponsor: Montreal Heart Institute

New P3 trial • Cardiovascular • Myocardial Infarction

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial. (PubMed, Int J Stroke) - P3 | "IntroductionLarge-vessel occlusion (LVO) stroke represents around one-third of all ischemic strokes; moreover, patients with symptomatic intracranial or extracranial arterial stenosis are at increased risk of stroke occurrence and early stroke recurrence.Several trials have evaluated the potential role of ticagrelor in ischemic stroke, SOCRATES trial which showed that ticagrelor was not superior to aspirin in decreasing the risk of stroke, heart attack, or death at 90 days in patients with minor ischemic stroke or TIA.When cilostazol was compared with aspirin and ticlopidine, it showed a comparable ability to inhibit platelet reactivity and aggregation to that produced by ticlopidine and aspirin. Additionally, cilostazol was associated with fewer hemorrhagic side effects.In Egypt, the monthly cost of cilosatzol 100 mg Bid is approximately half that of ticagrelor 90 mg Bid, making it a potentially cost-effective antiplatelet agent, especially in a country..."

Journal • Cardiovascular • Giant Cell Arteritis • Hematological Disorders • Ischemic stroke • Myocardial Infarction

Comparative Effectiveness of Clopidogrel vs. Potent P2Y12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real-World Cohort Study. (PubMed, Br J Clin Pharmacol) - "Among patients with MI with CYP2C19 NM undergoing percutaneous coronary intervention, the use of potent P2Y₁₂ inhibitors was associated with a reduced risk of thrombotic events at 1 year compared to clopidogrel. These findings indicate genotype-guided de-escalation strategies warrant further investigation across diverse clinical settings."

HEOR • Journal • Real-world evidence • Cardiovascular • Gastroenterology • CYP2C19

1-month safety results in a randomized controlled trial (COATING) evaluating a surface-modification flow diverter (p64-MW-HPC) under single antiplatelet treatment. (PubMed, J Neurointerv Surg) - "COATING is the first RCT to evaluate an SM FD (p64-MW-HPC) under SAPT and shows favorable safety at 1 month."

Journal • Cardiovascular • Vascular Neurology

Impact of Body Mass Index on Clinical Outcomes in Myocardial Infarction Patients Undergoing Coronary Stenting with Dual Antiplatelet Therapy. (PubMed, Biomedicines) - "Background: Dual antiplatelet therapy (DAPT), combining aspirin with a P2Y12 receptor inhibitor (P2Y12i), remains central to the management of acute myocardial infarction (MI), especially in patients undergoing percutaneous coronary intervention (PCI)...Patients were stratified into clopidogrel-based (n = 44,480) and potent P2Y12i-based (prasugrel or ticagrelor; n = 7639) DAPT cohorts... In patients with MI undergoing PCI, elevated BMI was paradoxically associated with more favorable short-term outcomes, including reduced mortality. Potent P2Y12i therapy demonstrated a consistent benefit across BMI categories, supporting its broad application irrespective of body mass."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Ticagrelor-Induced Complete Heart Block. (PubMed, Cureus) - "The patient was initiated on dual antiplatelet therapy with aspirin and ticagrelor...Ticagrelor was suspected as a plausible cause of CHB and was substituted with clopidogrel. This was followed by an intermittent return to sinus rhythm within 24 hours and complete resolution of CHB by 40 hours with no further episodes of CHB occurring after 48hours of discontinuation of ticagrelor. This case highlights the potential for ticagrelor-induced CHB even in young individuals without any preexisting conduction system disease and the importance of early recognition and prompt management, which can prove to be lifesaving."

Journal • Cardiovascular • Myocardial Infarction • Pain

De-Escalation Dual Antiplatelet Strategy in Stabilized Myocardial Infarction Patients With Diabetes Mellitus. (PubMed, JACC Cardiovasc Interv) - "In MI patients with DM, 1-month unguided de-escalation to clopidogrel after ticagrelor-based DAPT was associated with clinical benefit without increasing ischemic risk. These results warrant further prospective validation."

Clinical • Journal • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction

Self-limiting recovery from subacute haemorrhagic pericardial tamponade following early ST-segment elevation myocardial infarction: a case report. (PubMed, Eur Heart J Case Rep) - "Discontinuation of the anticoagulant agent and ticagrelor resulted in gradual PE resolution, with complete absorption achieved after 1.5 months. This case highlights the potential development of haemorrhagic pericardial tamponade from small-to-moderate PE following early STEMI, particularly under intensive antithrombotic therapy in patients with transmural myocardial infarction. It also illustrates a rare, self-limiting course of haemorrhagic pericarditis, with CMR imaging supporting conservative management as a viable option in carefully selected patients."

Journal • Cardiovascular • Ischemic stroke • Myocardial Infarction • Pain • Pulmonary Disease

Aspirin monotherapy or DAPT after CABG in ACS? Insights from the TACSI Trial. (PubMed, Indian J Thorac Cardiovasc Surg) - "Ticagrelor plus aspirin did not reduce death, myocardial infarction, stroke, or repeat revascularization compared with aspirin alone at 1 year, but nearly doubled the risk of major bleeding. This challenges the assumption that DAPT, which is recommended in all cases after ACS, provides added benefit after CABG."

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

CytoSorb® hemoadsorption for emergency aortic surgery after ticagrelor loading. (PubMed, Indian J Thorac Cardiovasc Surg) - No abstract available

Journal

Study protocol for low-dose evaluation of aspirin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (LEAST): a multicenter, double-blind, randomized controlled clinical trial. (PubMed, Ann Med) - P4 | "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is standard treatment for ST-elevation myocardial infarction (STEMI). The LEAST trial addresses an important knowledge gap regarding optimal aspirin dosing in Chinese STEMI patients and may influence future guideline recommendations for acute coronary syndrome management in Asian populations. ClinicalTrials.gov (NCT06756945)."

Clinical • Clinical protocol • Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Topical 5-Aminolevulinic Acid Photodynamic Therapy-induced Purpura: Involvement of Dual Antiplatelet Therapy (DAPT). (PubMed, Photodiagnosis Photodyn Ther) - "We report a case involving a 69-year-old man receiving dual antiplatelet therapy (DAPT) with aspirin and ticagrelor who developed unexpected purpura on both forearms following PDT with 5-aminolevulinic acid for actinic keratoses...After modification of the antiplatelet regimen to include aspirin and clopidogrel, platelet function normalized and the purpura resolved...This report highlights the impact of PDT on platelets and the microcirculation, suggesting that antiplatelet-associated platelet dysfunction may predispose patients to cutaneous bleeding. For enhanced procedural safety and optimal therapeutic outcomes, we recommend comprehensive assessment with PFT before PDT for patients receiving DAPT."

Journal • Actinic Keratosis • Cardiovascular • Dermatology

The Impact of Cangrelor in the UK for the Treatment of STEMI Patients with Gastric Absorption Issues Undergoing Percutaneous Coronary Intervention. (PubMed, J Clin Med) - "Oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban), and aspirin and heparin alone were included as base case comparators. The introduction of cangrelor is estimated to lead to 314 fewer hospital days and 190 clinical events avoided over 5 years. Introducing cangrelor to STEMI patients with gastric absorption issues undergoing PCI in the UK is estimated to generate a small cost saving and reduced length of stay for some patients."

Journal • Cardiovascular • Myocardial Infarction

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications. (PubMed, Heart Fail Clin) - "The CYP2C19 enzyme metabolizes clopidogrel, a prodrug, to its active form. Prasugrel or ticagrelor is recommended in those with an LoF allele as neither is affected by CYP2C19 genotype. Although data demonstrate improved outcomes with a CYP2C19-guided approach to P2Y12 inhibitor selection, genotyping has not yet been widely adopted in clinical practice."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • CYP2C19

Impact of dual antiplatelet therapy within 72 hours post mild ischemic stroke and transient ischemic attack: meta-analysis. (PubMed, Brain Inj) - "However, the evidence regarding bleeding risk with aspirin and ticagrelor remains highly uncertain, as the estimates are imprecise with extremely wide confidence intervals, and no definitive conclusions can be drawn. Aspirin plus dipyridamole may be a safer, equally effective alternative, underscoring the need for individualized treatment based on thrombotic and hemorrhagic risks."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Ischemic stroke

Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update. (PubMed, Curr Neurol Neurosci Rep) - "Current data suggests reversal of vitamin K antagonists with intravenous vitamin K and 4-factor prothrombin complex concentrates (4f-PCC), reversal of dabigatran with idarucizumab, and reversal or direct oral factor Xa inhibitors with either 4f-PCC or andexanet-alfa. While platelet transfusion is not suggested for antiplatelet-associated ICH, DDAVP may be reasonable, and a new reversal agent is under development for ticagrelor. Rapid reversal of antithrombotic-associated coagulopathy in the context of ICH may prevent ICH expansion and improve neurological outcomes."

Journal • Review • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach. (PubMed, Turk J Pharm Sci) - "Visual observation of the dissected gastric organ through a stereomicroscope revealed no redness or bleeding post-administration of Ticagrelor SD formulations. The SD technique with carrier co-povidone VA 64 and vitamin E TPGS prepared by the solvent evaporation process could yield a Ticagrelor formulation with improved bioavailability and polymorphic stability."

Journal • Gastroenterology • Gastrointestinal Disorder

Targeting neuroinflammatory pathways in epilepsy: a combined network-pharmacology and in vivo study of dapagliflozin and ticagrelor. (PubMed, Inflammopharmacology) - "The higher co-localisation of GFAP in hippocampal tissues indicated astrogliosis. However, dapagliflozin and ticagrelor significantly ameliorated these alterations, indicating both drugs possess anticonvulsant activity."

Journal • Preclinical • CNS Disorders • Epilepsy • Inflammation • GFAP • TLR4